Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Germline CEBPA-mutant acute myeloid leukaemia (AML) is uncommon. There have been reports of single kindreds and small series1–6 since its initial description in 2004;7 and the most comprehensive characterisation comprising 10 CEBPA-mutant families was recently published.8 We herein describe another patient with AML with a germline CEBPA mutation encountered in our haematology practice.
The patient was a 33-year-old Vietnamese man who presented with a 2-week history of easy bruising and generalised fatigue. Initial investigations revealed haemoglobin of 11.6 g/dL, white cell count of 3.98×109/L and platelet count of 35×109/L. His marrow was moderately hypercellular with increased pleomorphic blasts, consistent with AML subtype M2 (figure 1). Of note, occasional pelgeroid neutrophils were observed. Flow cytometry was performed using a panel of markers, which included CD7, CD15, CD34, CD36, CD45, CD56, CD71, CD117 and HLA-DR. This revealed the presence of CD34-positive myeloblasts (comprising 5.8% of total cells), as well as dys-coordinated granulopoiesis (with partial CD56 expression) and markedly dysplastic erythropoiesis (with partial CD36/CD71 expression), overall suggestive of clonal evolution from a myelodysplastic syndrome (MDS). Cytogenetic analysis revealed a 46,XY,del(9)(q13q22) karyotype. CEBPA mutational analysis by Sanger sequencing revealed two mutations: c.134dupC and c.937_938ins33 (figure 2).
He was started on induction chemotherapy, and flow cytometric analysis of the bone marrow postinduction revealed 0.8% minimal residual disease (MRD). Unexpectedly, CEBPA mutational analysis revealed persistence of the c.134dupC mutation, raising the suspicion of a germline CEBPA mutation. This was subsequently confirmed by CEBPA mutational …
Contributors BY, ESCK, W-JC and LPK contributed to study design. CN, KB, P-LL, ES, and LC contributed to data generation. GM, T-CL and CHN contributed to data analysis and interpretation.
Competing interests None declared.
Patient consent Obtained.
Ethics approval NUHS Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.